Suppr超能文献

糖尿病患者群体中,微粒体与前体细胞的关系可作为血管健康的衡量指标。

Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population.

机构信息

Science Foundation Ireland (SFI), Wilton Park House, Dublin 2, Ireland.

出版信息

Cytometry B Clin Cytom. 2010 Sep;78(5):329-37. doi: 10.1002/cyto.b.20528. Epub 2010 Jun 11.

Abstract

OBJECTIVE

Quantitative measures are needed to identify diabetic patients at higher risk for CV events. Cell-derived microparticles (MPs) are submicron membrane vesicles released from activated cells that are indicative of cell damage. Progenitor cells (PCs) including proangiogenic cells (PACs), often termed endothelial progenitor cells (EPCs), are mediators of reparative capacity. We examined whether the relationship of MPs to PCs/PACs could be used as an improved and clinically feasible index of vascular pathology.

METHODS AND RESULTS

Plasma samples were collected from patients with early-stage (ES, Diagnosis < 1 year) and long-term (LT, Diagnosis > 5 years,) Type 2 diabetes and compared with age related healthy subjects (H). PC and MP subtypes were measured by a combination of flow cytometry and ELISA-based methods. The ratio of procoagulant MPs/CD34(+) PCs proved a valuable index to distinguish between subject groups (P = 0.01). This index of compromised vascular function was highest in the LT group despite intensive statin therapy and was more informative than a range of soluble protein biomarkers.

CONCLUSIONS

This is the first report of a relationship between MPs and PCs in Type 2 diabetes. This ratio may provide a quantitative and clinically feasible measurement of vascular dysfunction and cardiovascular risk in patients with diabetes. © 2010 International Clinical Cytometry Society.

摘要

目的

需要定量指标来识别发生心血管事件风险较高的糖尿病患者。细胞来源的微颗粒(MPs)是从激活细胞释放的亚微米膜囊泡,提示细胞损伤。祖细胞(PCs)包括促血管生成细胞(PACs),通常称为内皮祖细胞(EPCs),是修复能力的介质。我们研究了 MPs 与 PCs/PACs 的关系是否可以作为血管病理的一种改进且临床可行的指标。

方法和结果

从早期(ES,诊断<1 年)和长期(LT,诊断>5 年)2 型糖尿病患者和年龄相关的健康受试者(H)中采集血浆样本,并进行比较。通过流式细胞术和 ELISA 为基础的方法组合来测量 PC 和 MP 亚型。促凝 MPs/CD34(+) PCs 的比值证明是区分各组受试者的有价值指标(P=0.01)。尽管进行了强化他汀类药物治疗,但 LT 组的血管功能受损指数最高,比一系列可溶性蛋白生物标志物更具信息量。

结论

这是首次在 2 型糖尿病患者中报告 MPs 与 PCs 之间的关系。该比值可能为糖尿病患者血管功能障碍和心血管风险提供一种定量且临床可行的测量方法。 © 2010 国际临床细胞化学学会。

相似文献

5
Microparticles and type 2 diabetes.微粒与2型糖尿病
Diabetes Metab. 2008 Feb;34 Suppl 1:S27-32. doi: 10.1016/S1262-3636(08)70100-9.
6
Dynamic role of microparticles in type 2 diabetes mellitus.微粒在2型糖尿病中的动态作用
Curr Diabetes Rev. 2009 Nov;5(4):245-51. doi: 10.2174/157339909789804404.
9
Treatment options for low high-density lipoproteins.低高密度脂蛋白的治疗选择。
Curr Opin Endocrinol Diabetes Obes. 2014 Apr;21(2):134-9. doi: 10.1097/MED.0000000000000049.

引用本文的文献

1
Inertial Microfluidics Enabling Clinical Research.助力临床研究的惯性微流控技术
Micromachines (Basel). 2021 Mar 3;12(3):257. doi: 10.3390/mi12030257.
6
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.糖尿病中的内皮功能障碍:发病机制、意义及治疗
Rev Diabet Stud. 2013 Summer-Fall;10(2-3):133-56. doi: 10.1900/RDS.2013.10.133. Epub 2013 Aug 10.

本文引用的文献

4
Hypercholesterolemia-associated endothelial progenitor cell dysfunction.高胆固醇血症相关的内皮祖细胞功能障碍。
Ther Adv Cardiovasc Dis. 2008 Oct;2(5):329-39. doi: 10.1177/1753944708094769. Epub 2008 Aug 21.
7
Function and role of microparticles in various clinical settings.微粒在各种临床环境中的功能和作用。
Thromb Res. 2008;123(1):8-23. doi: 10.1016/j.thromres.2008.06.006. Epub 2008 Jul 29.
8
Role of microparticles in atherothrombosis.微粒在动脉粥样硬化血栓形成中的作用。
J Intern Med. 2008 May;263(5):528-37. doi: 10.1111/j.1365-2796.2008.01957.x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验